Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02269592 · ClinicalTrials.gov registry record
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
A clinical trial of Myelodysplastic Syndromes and Waldenstrom Macroglobulinemia, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- 10,000
- Enrollment target
- 7
- Study locations
NCT02269592 is a study of Myelodysplastic Syndromes and Waldenstrom Macroglobulinemia that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 10,000 participants, above the 227-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (4305% higher). The trial reports 7 study locations across 3 states.
The verdict
NCT02269592, a study of Myelodysplastic Syndromes and Waldenstrom Macroglobulinemia, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- 10,000 participants
- Enrollment target
- 7
- Study locations
Study Summary
Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the cancer or cells in blood. Several alterations that occur repeatedly in certain types of blood cancers have already been identified, and these discoveries have led to the development of new drugs that target those alterations. More remain to be discovered. Some of these abnormalities include alterations in genes. Genes are the part of cells that contain the instructions which tell the investigators bodies how to grow and work, and determine physical characteristics such as hair and eye color. Genes are composed of DNA letters that spell out these instructions. Studies of the DNA molecules that make up the genes are called "molecular" analyses. Molecular analyses are ways of reading the DNA letters to identify errors in genes that may contribute to an increased risk of cancer or to the behavior of the cancer cells. Some changes in genes occur only in cancer cells. Others occur in the genes that are passed from parent to child. This research study will examine both kinds of genes. The best way to find these genes is to study large numbers of people. The investigators expect that as many 1000 individuals will enroll in this study. This research study is trying to help doctors and scientists understand why cancer occurs and to develop ways to better treat and prevent it. To participate in this study the participant must have cancer now, had it in the past, or are at risk of developing cancer. The participant will not undergo tests or procedures that are not required as part of their routine clinical care. The investigators will ask the participant to provide an additional sample from tissue that is obtained for their clinical care including blood, bone marrow, or tissue sample. The investigators will also ask for a gentle scrape of the inside of their cheek, mouthwash or a skin sample to obtain their germline DNA
Conditions Studied
Study Locations (7)
Massachusetts
- Dana-Farber Cancer Institute - Boston
- Dana Farber Cancer Institute at St. Elizabeth's - Brighton
- Dana Farber Cancer Institute at Merrimack Valley - Methuen
- Dana Farber Cancer Institute at Milford Regional Medical Center - Milford
- Dana Farber Cancer Institute at South Shore - Weymouth
Michigan
- West Michigan Cancer Center - Kalamazoo
New Hampshire
- Dana Farber/New Hampshire Oncology-Hematology - Londonderry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2014-08 |
| Est. Completion | 2030-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02269592
The ClinicalTrials.gov registry entry for NCT02269592 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 10,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 227-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (4305% higher). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 0 interventions.
NCT02269592 reports 7 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Michigan, New Hampshire.
Frequently Asked Questions
What is clinical trial NCT02269592 about?
NCT02269592 is a clinical study titled "Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome". Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the cancer or cells in blood. Several alterations that occur repeatedly in certain types of blood cancers have already been identified, and these d...
What is the current status of trial NCT02269592?
This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 2014-08. Estimated completion is 2030-09.
What conditions does trial NCT02269592 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Waldenstrom Macroglobulinemia, Smoldering Multiple Myeloma, Hematological Malignancies, Monoclonal Gammopathy of Undetermined Significance (MGUS).
Who is sponsoring clinical trial NCT02269592?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02269592 being conducted?
This trial has 7 study locations across Massachusetts, Michigan, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
RECRUITING · Phase 2
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
Explore more on PlainTrial
Myelodysplastic Syndromes
All registered trials for this condition
Waldenstrom Macroglobulinemia
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.